Nemtabrutinib, Zilovertamab vedotin, Nemtabrutinib, Nemtabrutinib, Nemtabrutinib
MK-2140-006
Phase 2 small_molecule active
Quick answer
Nemtabrutinib, Zilovertamab vedotin, Nemtabrutinib, Nemtabrutinib, Nemtabrutinib for Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome) is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active